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Antiviral mechanismV) is a highly pathogenic member of the family Bunyaviridae that needs to be
handled under biosafety level (BSL) 3 conditions. Here, we describe reverse genetics systems to measure
RVFV polymerase activity in mammalian cells and to generate virus-like particles (VLPs). Recombinant
polymerase (L) and nucleocapsid protein (N), expressed together with a minireplicon RNA, formed
transcriptionally active nucleocapsids. These could be packaged into VLPs by additional expression of viral
glycoproteins. The VLPs resembled authentic virus particles and were able to infect new cells. After infection,
VLP-associated nucleocapsids autonomously performed primary transcription, and co-expression of L and N
in VLP-infected cells allowed subsequent replication and secondary transcription. Bunyaviruses are potently
inhibited by a human interferon-induced protein, MxA. However, the affected step in the infection cycle is
not entirely characterized. Using the VLP system, we demonstrate that MxA inhibits both primary and
secondary transcriptions of RVFV. A set of infection assays distinguishing between virus attachment, entry,
and subsequent RNA synthesis conﬁrmed that MxA is able to target immediate early RNA synthesis of
incoming RVFV particles. Thus, our reverse genetics systems are useful for dissecting individual steps of RVFV
infection under non-BSL3 conditions.
© 2008 Elsevier Inc. All rights reserved.Introduction
Rift Valley fever virus (RVFV) is a serious emerging pathogen
affecting humans and livestock in sub-Saharan Africa, Egypt, Yemen,
and Saudi Arabia. Since the ﬁrst description of an outbreak in Kenya in
1931 (Daubney et al., 1931), there have been recurrent epidemics,
killing thousands of animals, hundreds of humans, and causing
signiﬁcant economic losses (Balkhy and Memish, 2003). To animals,
RVFV is mainly transmitted by mosquitoes, but humans are often
infected by close contact with infected animal material (Morrill and
McClain, 1996). A wide array of symptoms is connected with the
human disease, ranging from an uncomplicated acute febrile illness to
retinitis, hepatitis, meningoencephalitis, severe hemorrhagic disease,
and death (Balkhy and Memish, 2003). The severity of RVFV zoonosis
as well as the capability to cause major epidemics in livestock andg.de (F. Weber).
edicine Goettingen, D-37075
l rights reserved.humans has prompted authorities to list RVFV as a notiﬁable disease
and a potential biological weapon (Borio et al., 2002).
RVFV belongs to the genus Phlebovirus, family Bunyaviridae
(Elliott, 1997). Bunyaviruses are enveloped and have a tri-segmented
single-strand RNA genome of negative or ambisense polarity. They
replicate in the cytoplasm and bud into the Golgi apparatus. RVFV
encodes ﬁve structural proteins: the viral polymerase (L) on the large
(L) segment, two glycoproteins (Gn and Gc) and the 78 kDa protein on
the medium (M) segment, and the viral nucleocapsid protein (N) on
the smallest (S) segment (Struthers et al., 1984). RVFV also expresses
two nonstructural proteins, encoded on the M segment (termed NSm)
and the S segment (termed NSs). These accessory proteins are
dispensable for viral multiplication in cell culture (Gerrard et al.,
2007; Vialat et al., 2000;Won et al., 2006), but play important roles for
pathogenesis in vivo. NSm was found to suppress virus-induced
apoptosis (Won et al., 2007) and to enhance intrahost viral spread
(Bird et al., 2007a), whereas NSs is important to suppress the antiviral
interferon system (Billecocq et al., 2004; Bouloy et al., 2001; Le May
et al., 2004, 2008).
The general features of RVFV transcription and replication are
similar to those of other negative-stranded RNA viruses (Elliott, 1996).
Fig. 1. Minireplicon system for RVFV. Human 293T cells were transfected with
expression plasmids for the nucleocapsid protein (N) and the viral polymerase (L),
together with a minireplicon construct containing the Ren-Luc reporter gene in
antisense ﬂanked by the untranslated regions of the M segment (vM-Ren). As a negative
control the L expression plasmid was omitted. An FF-Luc plasmid was cotransfected to
control transfection efﬁciency. Cell lysates were assayed 24 h post transfection for Ren-
Luc and FF-Luc activity. Luciferase counts were normalized to the negative control,
numbers on top of each column indicate fold induction. Absolute luciferase values were
in the range of 105 and 106 relative light units for Ren-Luc and FF-Luc, respectively (data
not shown). Results from a representative experiment are shown.
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(UTRs) on both the 3′ and the 5′ ends that serve as promoters for
replication of the segment and for transcription of the encoded
reading frames. The vRNAs are encapsidated by N protein and
associate with L protein to form ribonucleoprotein particles (RNPs).
The RNPs are functional templates for mRNA synthesis and RNA
replication by the viral polymerase.
After glycoprotein-mediated entry into the cytoplasm, the nega-
tive-sense vRNAs of RVFV are transcribed into mRNAs by the RNP-
associated L and N proteins (“primary transcription”). The products of
these immediate early mRNAs then provide the machinery for
replication of the genome and further mRNA synthesis (“secondary
transcription”), and later drive the packaging of newly assembled
RNPs into budding particles. A speciﬁc feature of bunyaviruses is that
their mRNA synthesis is strictly dependent on host translation
(Bellocq and Kolakofsky, 1987; Ikegami et al., 2005b; Vialat and
Bouloy, 1992). Most likely, ongoing translation prevents premature
termination of transcription by destroying inhibitory secondary
structures which build up on the nascent mRNA (Barr, 2007).
The infection cycle of bunyaviruses is strongly inhibited by the
human interferon-induced protein MxA (Frese et al., 1996). MxA is a
cytoplasmic, large dynamin-like GTPase with antiviral activity against
a wide range of RNA viruses (Haller and Kochs, 2002; Haller et al.,
2007). The antiviral power of MxA against bunyaviruses is best
demonstrated by the protection of MxA transgenic mice from a lethal
dose of La Crosse bunyavirus (LACV) (Hefti et al., 1999). A functional
GTP binding activity is crucial for the antiviral activity of MxA, and
biochemical analysis suggested a physical interaction of newly
synthesized viral N protein with GTP-bound MxA (Kochs et al.,
2002). This interaction resulted in the formation of large, oligomeric
MxA/N copolymers that accumulate in virus-infected cells (Kochs et
al., 2002). The current model is that depletion of free N by MxA cuts
viral RNPs off the N supply, thus leading to a strong inhibition of
bunyaviral RNA replication and secondary transcription (Reichelt et
al., 2004). However, the question whether primary transcription of
bunyaviruses is also affected, as was described for vesicular stomatitis
virus and the Thogoto-Orthomyxovirus (Kochs and Haller, 1999;
Pavlovic et al., 1992), is still unsolved. This lack of data is caused by the
experimental hurdle that bunyavirus transcription is blocked by
translation inhibitors, the traditional means to separate primary
transcription from later steps.
Reverse genetics systems to rescue infectious RVFV entirely from
cloned cDNA plasmids have been developed (Billecocq et al., 2008;
Gerrard et al., 2007; Habjan et al., 2008; Ikegami et al., 2006). These
systems allow the targeted manipulation of the viral genome and
proved to be extremely useful to demonstrate the contribution of NSs
and the NSm proteins to viral pathogenesis (Bird et al., 2007a; Ikegami
et al., 2006) and to identify transcriptional termination signals
(Albarino et al., 2007; Ikegami et al., 2007). However, research with
these recombinant RVFV systems is hampered and restricted since the
pathogen can only be handled under biosafety level 3 (BSL3)
conditions. Therefore, it would be desirable to have tools at hand
which allow to study aspects of RVFV infection cycle and the host
response under non-BSL3 conditions.
Here, we report the establishment of a RVFV reverse genetics
systemwhich recapitulates individual steps of the replication cycle in
a modular manner. A minireplicon system was developed to measure
RVFV polymerase activity. Additional expression of viral glycoproteins
allowed efﬁcient and helper-free packaging of minireplicon RNPs into
virus-like particles (VLPs) which were released into the medium. By
incubating cells with VLPs, we were able to reconstitute the ﬁrst steps
of RVFV infection. Importantly, our system allowed us to demonstrate
that the L polymerase complexed with incoming RNPs is highly active
in primary transcription. Furthermore, if both L and the nucleoprotein
N are additionally provided in trans, RNPs are active in replication as
well. Using this modular approach we demonstrate that the humanMxA protein is able to interfere with viral primary transcription, thus
blocking RVFV early in infection.
Results and discussion
Establishment of a RVFV minireplicon system
Minireplicon systems are useful tools to investigate viral poly-
merase activity and promoter sequences. Bunyavirus minireplicon
systems usually consist of a reporter gene ﬂanked by viral 5′ and 3′
UTRs, and recombinant L and N proteins (Accardi et al., 2001; Blakqori
et al., 2003; Dunn et al., 1995; Gauliard et al., 2006; Ikegami et al.,
2005a; Weber et al., 2001). The reporter construct is transfected into
mammalian cells along with the L and N expression constructs and
will be transcribed intracellularly into a minireplicon resembling a
viral gene segment. The products of the expression constructs
encapsidate, transcribe and replicate the minireplicon, thus resulting
in reporter activity.
For RVFV, minireplicon systems based on the coexpressed RNA
polymerase of the bacteriophage T7 have been established earlier
(Accardi et al., 2001; Gauliard et al., 2006; Ikegami et al., 2005a).
We decided to generate a T7-independent version in which the
expression constructs were under control of a promoter for the
cellular RNA polymerase II (RNAP II), and the minireplicon was
transcribed intracellularly by RNAP I. The L and N genes were
expressed by the mammalian expression vector pI.18. A mini-
replicon consisting of the antisense gene for the Renilla Luciferase
(Ren-Luc) ﬂanked by RVFV M segment UTRs was cloned into the
RNAP I vector pHH21 (Neumann et al., 1999). Human 293T cells
were transfected with these plasmids, and minireplicon activity
was assessed by measuring Ren-Luc activity of cell extracts after
overnight incubation. Fig. 1 shows that coexpression of L, N and
the minireplicon upregulated the Ren-Luc activity (black bars),
whereas omission of the L construct resulted in low activity. As the
minireplicon plasmid was designed to produce negative sense RNA,
Ren-Luc activity clearly indicates successful packaging of RNA into
RNPs and transcription by L and N. Moreover, the expression of an
internal control, consisting of the RNAP II-driven gene for the
ﬁreﬂy luciferase (FF-Luc), was independent of the full set of RVFV
plasmids (Fig. 1, grey bars), as expected. Thus, our RVFV
minireplicon system which is entirely based on the activity of
cellular RNA polymerases was able to efﬁciently reconstitute
recombinant RVFV RNPs.
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VLP systems consisting of minireplicon RNPs packaged by viral
glycoproteins have been established for two bunyaviruses, Bunyam-
wera virus and Uukuniemi virus. These systems have proven useful for
the analysis of particle assembly and RNP packaging (Overby et al.,
2007a, 2006, 2007b; Shi et al., 2006). To generate VLPs of RVFV, we
transfected anM expression construct (encoding Gn, Gc, NSm, and the
78 kDa protein) together with the minireplicon system plasmids into
293T cells (donor cells). Twenty-four hours later, supernatants were
harvested and used to infect BSR-T7/5 cells expressing RVFV L and N
(indicator cells). An outline of the experiment is provided in Fig. 2A.
Two additional measures were taken to minimize unspeciﬁc
reporter activities in indicator cells caused by carryover transfection.
Firstly, any residual plasmids in the VLP supernatants were destroyed
by extensive treatment with DNase. Secondly, the species-speciﬁcity
of the human RNAP I-driven minireplicon construct excluded back-
ground expression in the non-human indicator cells in the possible
case of unwanted transfection. Moreover, RNAP II-driven coexpression
of FF-Luc in donor cells served as a speciﬁcity control, because the FF-
Luc RNA lacks any RVFV sequences and should therefore not be
packaged into VLPs. Reporter assays demonstrated the speciﬁc
minireplicon activity mediated by L and N (Fig. 2B, left panel).
Coexpression of the M segment-encoded glycoproteins had no
detrimental effects on reporter activity. Importantly, only the super-
natant of cells that had been co-transfected with the M expression
construct produced a strong Ren-Luc activity in indicator cells (Fig. 2B,Fig. 2. Formation of RVFV VLPs. (A) Outline of the procedure used to generate VLPs. Donor c
together with the reporter minireplicon construct vM-Ren. Release of VLPs into the supernata
both N and L. (B) Luciferase activities in donor and indicator cells. 293T cells (donor cells) we
columns 1 and 2), or together with an RNAP II-driven M expression plasmid (left panel, colum
cells (right panel). FF-Luc and Ren-Luc activities in donor cells were measured after removal
were normalized to the experiment where L was omitted, and numbers on top of each coluright panel). Transfer of FF-Luc activity, in contrast, was negligible.
These data imply that coexpression of the M segment-encoded genes
results in efﬁcient and speciﬁc packaging of minireplicon RNPs into
VLPs, which are subsequently released into the medium and are able
to infect new cells.
RVFV VLPs resemble authentic virions
To further characterize the VLPs, we analyzed their immunological
characteristics, protein composition and morphology. Firstly, VLP-
containing supernatants were incubated with different antisera
derived from RVFV-infected mice or humans, and then used to infect
indicator cells expressing RVFV L and N. A strong reduction in Ren-Luc
activity occurred in indicator cells when RVFV-speciﬁc antisera were
used (Fig. 3A). In contrast, a control antibody directed against the
LACV Gc envelope protein as well as sera from an uninfected mouse or
individual had no inﬂuence on the reporter activity. These results
indicate that the VLPs were speciﬁcally neutralized by RVFV-speciﬁc
antisera.
Secondly, we determined the protein composition of VLPs. Super-
natants from 293T cells transfected with different plasmid combina-
tions were concentrated by ultracentrifugation and subjected to
Western blot analysis. Supernatants from RVFV-infected cells served
as positive control (Fig. 3B, lane 1). As expected, there was no release
of viral proteins from minireplicon-expressing cells lacking glycopro-
tein expression (Fig. 3B, lane 3). However, when the full set of
plasmids for the VLP system had been transfected, both the viral Gnells were transfected with expression plasmids for N, L and the viral glycoproteins (M),
nt of donor cells was detected by transfer of supernatants onto indicator cells expressing
re transfected with minireplicon system plasmids alone as described in Fig. 1 (left panel,
n 3). Supernatants (1 ml) were collected 24 h later and used to infect BSR-T7/5 indicator
of supernatants, and indicator cells were analyzed 24 h post infection. Luciferase counts
mn display fold induction. Results from a representative experiment are shown.
Fig. 3. VLPs resemble authentic RVFV particles. (A). Neutralization of VLPs by RVFV-
speciﬁc antisera. VLP-containing supernatants (100 μl) were incubated with 5 μl of
mouse or human antisera speciﬁc for RVFV for 1 h at 37 °C. As controls, 5 μl of serum
from a non-seroconverted mouse and human (ctrl) or 5 μl of a monoclonal antibody
against La Crosse bunyavirus glycoprotein Gc (anti-LACV MAb) were used. RVFV N and
L-expressing indicator cells were then infected with antibody-treated or untreated VLP
preparations, or the supernatant from minireplicon-expressing cells (SN MR). Ren-Luc
activity was measured 24 h later and is shown as percent activity of untreated VLPs.
Mean values and standard deviations were calculated from three independent
experiments. (B) Western blot analysis of RVFV particles and VLPs. Concentrated
supernatants from RVFV Clone 13-infected cells (lane 1) and 293T cells transfected with
different plasmid combinations (lanes 2 to 4) were analyzed byWestern blotting using a
monoclonal antibody speciﬁc for RVFV Gn and 78 kDa protein (upper panel), and an
antibody against the nucleoprotein N (lower panel). (C) Negative staining TEM of
concentrated VLPs and RVFV particles (2 examples shown for each) ﬁxed with
glutaraldehyde and stained with uranyl acetate. Scale bar represents 50 nm.
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This indicates that the composition of VLPs is similar to that of RVFV
particles. We noted, however, that the relative proportion of the
78 kDa protein (which is recognized by the monoclonal antibody
against Gn) was substantially higher in the VLPs than in the authentic
virus particles. This might be due to space restrictions inside the RVFV
particles compared to the single-segmented VLPs, since the 78 kDa
protein probably contains an additional cytoplasmic tail compared to
Gn (Gerrard and Nichol, 2007). Another possibility is that the
expression of the M segment-encoded proteins and their incorpora-
tion into particles differs slightly between plasmid-transfected and
virus-infected cells. Notably, we were unable to detect release of
glycoproteins in the absence of a co-transfected minireplicon system
(data not shown). This is in contrast to results obtained with the VLP
system of the related Phlebovirus Uukuniemi for which it was shown
that overexpressed glycoproteins are sufﬁcient to form VLPs that are
released into the supernatant (Overby et al., 2007a; Overby et al.,
2006). Apparently, RVFV requires additional structural components
for assembly and release of VLPs.
Finally, we compared the structure of VLPs and RVFV particles
using negative stain transmission electron microscopy (TEM). Super-
natants with VLPs or RVFV particles were concentrated by ultracen-
trifugation, ﬁxed with glutaraldehyde at pH 7.4 and stained with
uranyl acetate. The negative stain pictures shown in Fig. 3C
demonstrate that VLPs resemble RVFV particles in size and
morphology.
Together, these data indicate that the VLPs which we generated by
coexpression of the minireplicon system and the M-encoded
glycoproteins can serve as a model for authentic RVFV particles.
Optimization of VLP production
We performed a time-course analysis to study the kinetics of VLP
formation (Fig. 4). Donor cells were transfected with either the
minireplicon alone or together with the M expression construct used
to generate VLPs. Cell lysates and supernatants were harvested from
parallel dishes after 24, 48 or 72 h. Reporter assays of donor cell lysates
showed again that the addition of the M segment expression plasmid
had nomajor effect on minireplicon activity (Fig. 4A, columns 2 and 3;
see also Fig. 2B, left panel). Both the minireplicon and the VLP system
were strongly active until 48 h post-transfection, and displayed a
sharp decrease at the 72 h time point. This indicates robust and
continual production of recombinant RVFV components and, most
probably, exhaustion after longer expression times.
When supernatants of the time course were used to infect
indicator cells, reporter assays conﬁrmed that the M segment
expression plasmid was necessary to generate infectious VLPs (Fig.
4B). Moreover, VLP activities steadily increased in the supernatants
harvested from 24 h to 72 h after the transfection of donor cells. The
apparent discrepancy between donor cells (peak at 48 h time point)
and indicator cells (steady increase until 72 h) may simply be due to
the fact that VLPs are relatively stable and accumulate in the
supernatants over the whole time course, whereas gene expression
in donor cells fades out. Phlebovirus particles are indeed known to be
remarkably stable under various conditions (Hardestam et al., 2007).
To determine the stability of our RVFV VLPs, we incubated them for
3 days at 37 °C and compared their reporter activity to VLP
preparations which were either kept at −80 °C or incubated for
10 min at 95 °C. The experiments showed that the RVFV VLPs lose on
average only about 20% of their activity after 3 days at 37 °C (Fig. 4C).
This indicates that, during the time course of VLP production, the high
activity measured in the indicator cells at 72 h post-transfection (see
Fig. 4B) is most likely due to an accumulation of environmentally
stable VLPs.
To estimate VLP yields in terms of infectious units, we constructed
a GFP minireplicon plasmid and produced VLPs expressing GFP (GFP-
Fig. 4. Optimization of VLP production and VLP stability. VLPs were generated as
described in Fig. 2, and VLP release from donor cells was followed over the course of
three days. Supernatants from parallel dishes were harvested at the time points
indicated and used to infect indicator cells expressing N and L. (A) Ren-Luc and FF-Luc
activities in donor cells were measured upon removal of supernatants. (B) Analysis of
luciferase activities in indicator cells was performed 24 h post-infection. Luciferase
counts were normalized to the controls where L was omitted. Data from a
representative experiment are shown, numbers on top of each column displaying
fold induction. (C) Stability of RVFV VLPs at 37 °C. VLP-containing supernatants (100 μl)
were incubated for 3 days at 37 °C or for 10 min at 95 °C and compared with a
preparation of freshly thawed VLPs which had been stored at −80 °C. RVFV L- and N-
expressing indicator cells were infected with VLP preparations, or with the supernatant
from minireplicon-expressing cells (SN MR). Ren-Luc activity was measured 24 h later
and is shown as percent activity of the VLPs stored at −80 °C. Mean values and standard
deviations were calculated from three independent experiments.
404 M. Habjan et al. / Virology 385 (2009) 400–408VLPs). Supernatants of donor cells harvested at 72 h after transfection
were used to infect BSR-T7/5 cells which had been previously
transfected with L and N constructs. These indicator cells were infec-
ted with ten-fold serial dilutions of the GFP-VLP-containing super-
natants. After overnight incubation, GFP-positive indicator cells were
counted by ﬂuorescence microscopy and titers were calculated
accordingly. Table 1 shows that 3 independent repetitions of this
experiment yield titers of approximately 106 infectious particlesTable 1





a BSR-T7/5 indicator cells expressing RVFV L and N were incubated overnight with
10-fold dilutions of supernatants containing GFP-VLPs.
b VLP titers were calculated from the number of GFP-positive indicator cells and the
respective dilution step.perml. As a clearly detectable GFP signal in the indicator cells depends
on their successful transfectionwith L and N plasmids, these numbers
most likely represent an underestimate. RVFV infections typically
yield titers between 106 and 108 infectious particles per ml (Billecocq
et al., 2008; Gerrard et al., 2007; Habjan et al., 2008). Thus, although
the VLPs are unable to undergo several cycles of infection, their
plasmid-based production is only 10- to 100-fold less efﬁcient
compared to infectious RVFV particles.
Dissection of RVFV primary and secondary transcriptions using the
VLP system
Conventionally, primary transcription of negative-strand RNA
viruses is measured by using translational inhibitors, e.g. cyclohex-
imide. Cutting off the supply of newly synthesized viral proteins
allows to measure the activity of incoming polymerase complexes
without the ampliﬁcation loop established by genome replication.
However, the fact that bunyavirus mRNA transcription is strictly
dependent on concurrent translation (Ikegami et al., 2005b; Patterson
and Kolakofsky, 1984; Vialat and Bouloy, 1992) precludes the
dissection of primary and secondary transcriptions by pharmaceutical
means.
We investigated whether our VLP system allows the measurement
of RVFV primary transcription. BSR-T7/5 cells were infected with VLPs
and monitored by measuring Ren-Luc over a period of 48 h. To
distinguish between primary and secondary transcriptions of the
VLPs, the indicator cells were either left untransfected or were
transfected with constructs for the polymerase complex proteins N
and L prior to infection, respectively (Fig. 5). In parallel, supernatantsFig. 5. Primary and secondary transcriptions in VLP-infected cells. (A) BSR-T7/5 cells
were either mock transfected (open squares), or transfected with N and L expression
plasmids (ﬁlled squares) prior to infection with VLPs harbouring Ren-Luc RNPs. As a
negative control, cells transfected with N and L plasmids were infected with
supernatants from minireplicon-expressing donor cells in the absence of M expression
plasmid (crosses). Ren-Luc activities in VLP-infected cells were then measured at
different time points over a period of 48 h. (B) The same data is shown as in A, but with
the y-axis adjusted to visualize activity of VLPs inmock transfected indicator cells. Mean
values and standard deviations were calculated from three independent experiments.
405M. Habjan et al. / Virology 385 (2009) 400–408from minireplicon-expressing cells were used to detect potential
background reporter activity. As expected, we observed strong Ren-
Luc activity in VLP-infected cells where polymerase complexes were
present (Fig. 5A). This activity steadily increased until 48 h post-
infection, the last time point measured, indicating continuous
replication and transcription. Supernatants from minireplicon-only
transfected cells, by contrast, did not elicit any detectable Ren-Luc
activities as expected. Interestingly, a clear and reproducible Ren-Luc
activity over background was also measured in VLP-infected indicator
cells in the absence of additional N and L helper plasmids, albeit to a
much lower extent than in the presence of these plasmids (Fig. 5B).
Maximum activity was reached after 24 h and remained at an almost
constant level for further 24 h. This indicates that the VLP-associatedFig. 6. Inhibition of RVFV primary and secondary transcriptions by humanMxA. (A) The inﬂue
5 cells with 1.5 μg of an expression plasmid for wt MxA or the inactive mutant MxA(T10
harbouring Ren-Luc RNPs. Ren-Luc activities in cell lysates weremeasured 24 h later and the v
were calculated from three independent experiments. Equal amounts of lysates from a repre
MxA and RVFV N. (B) To study the effect of MxA on RVFV replication and secondary transcrip
N and L expression plasmids prior to VLP treatment. Reporter assays and Western blot anal
exerts its antiviral effect on RVFV. For the attachment assay, cells stably transfected with an
(MOI 10) for 1 h on ice, washed with PBS, and then the total RNA was extracted. For the ent
medium was added after the virus inoculum was removed. The cells were incubated for ano
remove any residual cell-attached virus before RNA extraction. RVFV RNA in the different sa
mock infected cells was used as control. Mean values and standard deviations from three inviral polymerase is active in primary transcription. The same
observation was also made in several other cell lines infected with
VLPs (data not shown). The established system thus enables the study
of RVFV primary transcription.
Effect of the antiviral protein MxA on RVFV transcription
The VLP system developed in this study enabled us to investigate
the effect of the antivirally active protein MxA on primary and
secondary transcriptions of RVFV. Indicator cells were transfected
with an expression construct for MxA and infected with RVFV VLPs.
The MxA mutant T103A served as a negative control. Fig. 6A (upper
part) shows that MxA expressed by indicator cells was capable ofnce of humanMxA on RVFV primary transcriptionwas analyzed by transfecting BSR-T7/
3A), respectively. Twenty-four hours post transfection, cells were infected with VLPs
alues of theMxA(T103A) control were set to 100%. Mean values and standard deviations
sentative experiment were used for Western blot analysis to conﬁrm expression of both
tion, 1.5 μg of plasmid for wt MxA or MxA(T103A) were cotransfected with 0.5 μg of each
ysis were performed as indicated. (C) Stage of the virus replication cycle at which MxA
MxA-expression plasmid (MxA) or an empty vector (CTRL) were inoculated with RVFV
ry and the RNA synthesis assays, cells were also infected on ice for 1 h, but prewarmed
ther 2 h (entry) or 5 h (RNA synthesis), washed with PBS, and trypsinated for 10 min to
mples was measured by real time RT-PCR and normalized to γ-actin mRNA. RNA from
dependent experiments are shown (rel.u., relative units).
406 M. Habjan et al. / Virology 385 (2009) 400–408reducing the reporter activity of incoming VLPs by at least 30%. This
indicates a weak but clearly inhibitory effect on viral primary
transcription. Moreover, if N and L support constructs were expressed
in addition to MxA, a similar inhibitory effect of about 50% was
observed (Fig. 6B, upper part). Western blot analyses for MxA and
RVFV Nwere performed to control recombinant gene expression (Figs.
6A and B, lower parts).
To further characterize the MxA-sensitive step in early RVFV
infection, we established a set of assays which allows to differentiate
between virus attachment, entry into the cytoplasm, and early RNA
synthesis (Aizaki et al., 2008). For the attachment assay, control cells
and cells stably expressing MxA (Frese et al., 1995) were infected
with RVFV for 1 h on ice, washed, and the RNA extracted. In the entry
and the RNA synthesis assays, cells were also infected for 1 h on ice
and washed, but then pre-warmed cell culture medium was added
and cells were incubated at 37 °C for another 2 h (entry) or 5 h (RNA
synthesis). For these assays, any cell-associated virus particles which
had not entered the cytoplasm were removed by trypsin treatment
before the RNA was extracted. Subsequently, in all samples the
presence of RVFV RNA was analyzed by real time RT-PCR (Bird et al.,
2007b) and normalized to the cellular γ-actin mRNA. Fig. 6C shows
that attachment of RVFV particles onto cells at the applied MOI of 10
results in an approximately 100,000-fold enrichment of viral RNA
over γ-actin mRNA. This was independent of the presence of MxA.
Similar observations were made for virus entry. However, if virus
particles were allowed to initiate RNA synthesis, a 10-fold multi-
plication of viral RNA occurred only in the control cells, whereas in
MxA-positive cells viral RNA levels did not increase after entry.
Although this assay does not distinguish between transcription and
replication, it shows that MxA efﬁciently inhibits early viral RNA
synthesis. By contrast, receptor binding or entry into the cytoplasm
are not affected.
Together with the data obtained with the VLPs (see Figs. 6A and B),
these results indicate that MxA is capable of interfering with primary
transcription of bunyaviruses. Hence, MxA interacts not only with the
soluble N protein to prevent RNA replication (Kochs et al., 2002), but
also with the incoming, already assembled RNPs. This overall
inhibition of RNP function eventually results in a strong reduction of
RVFV replication (Frese et al., 1996).
Our proposed mechanism is in line with the current model for the
molecular action of MxA against RNA viruses (Haller et al., 2007). For
Thogoto virus, a tick-transmitted Orthomyxovirus, it has been shown
that MxA directly interacts with viral RNPs in the cytoplasm and
prevents their translocation into the nucleus, the place of viral
transcription and replication (Kochs and Haller, 1999; Weber et al.,
2000). In accordance with our recent data on LACV (Reichelt et al.,
2004), we speculate that this interaction occurs at the surface of
smooth ER membranes where MxA accumulates. Membrane-bound
MxA was shown to directly bind viral nucleoprotein and most likely
RNPs, leading to copolymerization of these components into large
aggregates and thereby inhibiting viral transcription. Accordingly,
MxA might relocalize RNPs of RVFV to intracellular locations that are
not favourable for viral transcription.
Conclusions
We have established reverse genetics tools which enable the study
of RVFV RNP activity, virus assembly, cell infection, primary
transcription and antiviral mechanisms under non-BSL3 conditions.
The modular build-up of this system allows dissecting the viral
replication cycle in a systematic manner. A system to produce VLPs via
baculoviral expression of Gn, Gc, and N was recently published (Liu et
al., 2008). These particles physically resemble RVFV virions and are
able to induce cell–cell fusion after pH shift. Our VLPs, in contrast, are
more similar to RVFV particles as they contain active RNPs, infect
target cells, transcribe a gene of interest, and can be neutralized byRVFV-speciﬁc antisera. Furthermore, as we describe in an accompany-
ing vaccination paper (Näslund et al., 2009), the VLPs confer a high
level of protection from lethal RVFV infection. It is hoped that the
RVFV minireplicon and VLP systems might be instrumental for future
research on this important pathogen.
Materials and methods
Chemicals, cells and viruses
Geneticin G418 (Biochrom AG) was dissolved in H2O to 100 mg/ml
and used at a concentration of 1 mg/ml cell culture medium. BSR-T7/5
cells (Buchholz et al., 1999), Vero cells and 293T cells were cultivated
in Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented with
10% FCS. BSR-T7/5 cells were additionally providedwith G418 on every
second passage. MxA expressing cell clones VA9 and the control cell
line VN5 (Frese et al., 1995) were grown in DMEM with 5% serum
supplemented with G418. RVFV strain Clone 13 was propagated in
Vero cells.
Antibodies
The mouse monoclonal anti-LACV antibody #807-31 directed
against the viral Gc protein was kindly provided by Samantha Soldan
and Daniel Gonzales-Scarano, University of Pennsylvania (Gonzalez-
Scarano et al., 1982). The mouse control antiserum with speciﬁcity
for inﬂuenza A virus strain PR/8/34 was kindly provided by Otto
Haller. The human control serum was kindly provided by Ursula
Meyer-König, Dept of Virology, Freiburg, and the human anti-RVFV
sera #1, #2, and #3 were kindly obtained from Michele Bouloy
(Institute Pasteur, Paris, France) and Patricia A. Nuttall (NERC
Institute of Virology, Oxford, UK), respectively. The mouse mono-
clonal antibody 4D4 directed against the RVFV Gn and 78 kDa
proteins was kindly provided by Jonathan F. Smith, (USAMRIID, Fort
Detrick, USA). The mouse monoclonal antibody M143 for detection of
human MxA was described previously (Flohr et al., 1999). Polyclonal
mouse antisera recognizing RVFV N protein or RVFV particles were
produced by inoculating mice with either recombinant N protein or
RVFV strain Clone 13, respectively (A. Pichlmair and F. Weber,
unpublished).
Plasmids
All plasmids were generated using standard molecular cloning
techniques and conﬁrmed by DNA sequencing. PCR was carried out
withAccuPrimePfxDNAPolymerase (Invitrogen; for cloning purposes)
or Taq DNA Polymerase (Eppendorf; for diagnostic purposes).
The constructs pI.18_RVFV_L, pI.18-RVFV_N and pI.18-RVFV_M con-
taining the L, N and M segment coding sequences subcloned into the
eukaryotic expression plasmid pI.18 have been described previously
(Habjan et al., 2008). The reporter plasmid pHH21_RVFV_vMRen contains
the Renilla luciferase gene (Ren-Luc) in antisense orientation, ﬂanked by
the3′ and5′genomicuntranslated regions (UTRs) of theRVFVMsegment.
This reporter plasmid was generated by cloning the Ren-Luc gene,
ampliﬁed from plasmid pRL-SV40 (Promega) using speciﬁc oligonucleo-
tides (sequences available on request), into pHH21_RVFV_vMPro (Habjan
et al., 2008) via SapI restriction sites. Reporter plasmid
pHH21_RVFV_vMGFP encoding the enhanced green ﬂuorescent protein
(EGFP) instead of Ren-Luc was constructed in a similar manner. Plasmid
pGL3-control (Promega) expressesﬁreﬂy luciferase (FF-Luc) under control
of a mammalian RNA polymerase II promoter. Plasmid constructs
encoding human MxA and the GTPase-deﬁcient mutant T103A have
beendescribedpreviously (Pontenet al.,1997). For improvedexpression in
mammalian cells we cloned the corresponding coding sequences into
pI.18 via BamHI/EcoRI restriction sites, giving rise to plasmids pI.18-MxA
and pI.18-HA-MxA(T103A).
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Subconﬂuent monolayers of 293T cells in 12-well plates were
transfected with 0.4 μg each of pI.18_RVFV_N and pI.18_RVFV_L,
0.25 μg of pHH21_RVFV_vMRen, and 0.1 μg of pGL3-control using
3.5 μl Fugene HD transfection reagent (Roche) in 100 μl serum free
medium (OptiMEM; Invitrogen). In some experiments, speciﬁc
expression plasmids were omitted from the transfection mix. After
transfection, cells were incubated for the indicated times and lysed in
100 μl Dual Luciferase Passive Lysis Buffer (Promega). An aliquot of
20 μl of the lysate was assayed for FF-Luc and Ren-Luc activities as
described by the manufacturer (Promega).
Preparation of VLPs
Subconﬂuentmonolayers of 293Tcells in 6-well plates (donor cells)
were transfected with 0.5 μg of plasmids pI.18_RVFV_N, pI.18_RVFV_L,
pI.18_RVFV_M, pHH21_RVFV_vMRen, and with 0.1 μg of pGL3-control
using 6.3 μl Fugene HD transfection reagent. At the indicated time
points, supernatants were harvested and donor cells were lysed with
200 μl Passive Lysis Buffer to measure luciferase activities as described
above. The supernatants were treated with 1 μl/ml Benzonase
(Novagen) at 37 °C for 3 h and centrifuged at 12,000 ×g for 5 min to
remove cellular debris. Aliquots of the treated supernatants were then
used to infect new cells (indicator cells). In some experiments,
replication and transcription of RNPs was supported by transfecting
indicator cells with N and L expression plasmids pI.18_RVFV_N and
pI.18_RVFV_L (0.5 μg each) 16 h prior to the transfer of supernatant.
Titration of VLPs
GFP-expressing VLPs were generated in 6-well plates as described
above, using the minireplicon construct containing the GFP gene
(pHH21_RVFV_vMGFP) in place of the Renilla luciferase gene. Super-
natants containing VLPs were titrated on N and L expressing cells as
follows. First, BSR-T7/5 cells grown in 12-well plates were transfected
with 0.4 μg of each pI.18-RVFV-L and pI.18-RVFV-N using Nanofectin
transfection reagent (PAA Laboratories), and incubated overnight.
Then, cells were infected with ten-fold serial dilutions of GFP-VLP-
containing supernatants. Twenty-four hours post infection the
number of GFP-positive cells was determined by ﬂuorescence
microscopy and titers were calculated accordingly. Western blot
analysis conﬁrmed that the amounts of GFP-VLPs and the Ren-VLPs
used throughout the manuscript were comparable.
Transmission electron microscopy (TEM)
Supernatants containing Ren-VLPs or RVFV Clone 13 were
collected and clariﬁed by centrifugation (6000 ×g, 10 min, 4 °C), and
pH 7.4 was set by adding phosphate buffer (ﬁnal concentration of
50 μM). The particles were ﬁxed with glutaraldehyde (Sigma; ﬁnal
concentration of 0.5%) and centrifuged through a 20% (wt/vol) sucrose
cushion in TN buffer (50 mM Tris–HCl pH 7.4, and 100 mM NaCl) at
100,000 ×g for 2 h at 4 °C. The pellet was resuspended in TN buffer. For
TEM, aliquots of VLP or virus suspension were pipetted on EM grids
with a thin continuous carbon ﬁlm, washed once with TN buffer, and
stained for 1 min with 2% aqueous uranyl acetate. Images were
recorded at a calibrated magniﬁcation of 68,000× using a Tecnai F20
transmission electron microscope equipped with an Eagle CCD-
camera (FEI, Eindhoven, The Netherlands).
Western blot analysis
For detection of proteins in the supernatant of VLP-expressing or
RVFV Clone 13-infected cells, supernatants were collected and
clariﬁed from cell debris by centrifugation (6000 ×g, 10 min at 4 °C).The particles were concentrated by ultracentrifugation at 100,000 ×g
and 4 °C for 2 h, and the pellet was dried for 5min before resuspension
in phosphate-buffered saline (PBS). Proteins were separated by SDS-
PAGE and transferred to a PVDF membrane (Amersham), followed by
incubation in saturation buffer (PBS containing 10% non-fat dry milk
and 0.05% Tween). The membrane was then incubated for one hour
with primary antibodies, washed three times with 0.05% PBS-Tween,
and incubated with a horseradish-peroxidase (HRP)-conjugated
secondary antibody. After three additional washing steps, detection
was performed using the SuperSignal West Femto chemilumines-
cence kit (Pierce). Primary antibody concentrations used were 1:1000
for mouse-α-RVFV N, 1:2000 for mAbM143 and 1:5000 for mAb 4D4.
Attachment, entry, and RNA synthesis assays
Vero cells stably transfected with an MxA expression plasmid
(VA9) or an empty plasmid vector (VN5) (Frese et al., 1995) were
seeded in six-well dishes at 80% conﬂuency. Cells were infected with
RVFV strain Clone 13 at an MOI of 10 for 1 h on ice to allow
attachment but impede virus entry. After three washes with PBS,
RNA was extracted to assay the amount of cell-bound virus. To assay
the subsequent infection steps, virus inocula were removed after 1 h
of binding on ice, cells were washed, pre-warmed medium was
added, and the cells were incubated for another 2 h (entry) or 5 h
(RNA synthesis) at 37 °C, respectively. Before RNA extraction, cells
were once washed with PBS, trypsinated for 10 min, and again
washed three times with PBS to remove any cell-associated virus
which had not entered the cytoplasm.
Real time RT-PCR
All real-time RT-PCR reactions were performed with a Light-
Cycler 1.0 (Roche). One microgram of RNA was used to synthesize
cDNA with the Quantitect reverse transcription kit (Qiagen)
according to the manufacturer's recommendations. In the subse-
quent PCR reactions, the γ-actin mRNA was detected with
QuantiTect primers QT00996415 and the QuantiTect SYBR Green
RT-PCR Kit (Qiagen). RVFV RNA was detected as described by Bird et
al. (2007b) using the QuantiFast Probe PCR Kit (Qiagen), and
normalized to the γ-actin mRNA signal.
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